Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis

OBJECTIVE: Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yen Chih, Winokur, Paige, Blake, Andrew, Wu, Tianxia, Romm, Elena, Bielekova, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435700/
https://www.ncbi.nlm.nih.gov/pubmed/26000318
http://dx.doi.org/10.1002/acn3.181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435700/
https://www.ncbi.nlm.nih.gov/pubmed/26000318
http://dx.doi.org/10.1002/acn3.181

Ejemplares similares